VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses

• Main Authors: Yilan Shen (Author), Wei Chen (Author), Lei Han (Author), Qi Bian (Author), Jiajun Fan (Author), Zhonglian Cao (Author), Xin Jin (Author), Tao Ding (Author), Zongshu Xian (Author), Zhiyong Guo (Author), Wei Zhang (Author), Dianwen Ju (Author), Xiaobin Mei (Author)
• Format: Book
• Published: Elsevier, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Diabetic nephropathy (DN) is considered the primary causes of end-stage renal disease (ESRD) and is related to abnormal glycolipid metabolism, hemodynamic abnormalities, oxidative stress and chronic inflammation. Antagonism of vascular endothelial growth factor B (VEGF-B) could efficiently ameliorat...